Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
Fenioux C, Abbar B, Boussouar S, Bretagne M, Power JR, Moslehi JJ, Gougis P, Amelin D, Dechartres A, Lehmann LH, Courand PY, Cautela J, Alexandre J, Procureur A, Rozes A, Leonard-Louis S, Qin J; International ICI-Myocarditis Registry; Cheynier R, Charmeteau-De Muylder B, Redheuil A, Tubach F, Cadranel J, Milon A, Ederhy S, Similowski T, Johnson DB, Pizzo I, Catalan T, Benveniste O, Hayek SS, Allenbach Y, Rosenzwajg M, Dolladille C, Salem JE.
Fenioux C, et al.
Nat Med. 2023 Dec;29(12):3100-3110. doi: 10.1038/s41591-023-02591-2. Epub 2023 Oct 26.
Nat Med. 2023.
PMID: 37884625
First, using the international pharmacovigilance database VigiBase, the Assistance Publique Hopitaux de Paris-Sorbonne University data warehouse (Paris, France) and a meta-analysis of clinical trials, we show that ICI treatment of thymic epithelial tumors (TET, and particu …
First, using the international pharmacovigilance database VigiBase, the Assistance Publique Hopitaux de Paris-Sorbonne University dat …